In a transgenic mouse model lacking low‐density lipoprotein receptors (LDLR−/−), which are prone to developing atherosclerosis, treatment with FXR agonists led to a significant reduction of atherosclerotic lesions, suggesting that FXR activation can help to mitigate the development of atherosclerosis, a condition characterized by the accumulation of cholesterol‐rich plaques in arterial walls. The gene discussed is NR1H4; the disease is atherosclerosis.